Health Care/Hospital Global News & Press Release Distribution

Health Care/Hospital

All
APAC

Yeast Fuel, Developed by Chula's Faculty of Science Soon to Expand Its Production for the Aerospace Industry

Researchers from Chulalongkorn University have made use of forage grass to feed microorganisms and convert the resulting fat into jet fuel. They aim to expand petroleum-based oil replacement production to reduce impacts on human health and the environment. BANGKOK, ...

2024-04-24 00:00

Yeast Fuel, Developed by Chula's Faculty of Science Soon to Expand Its Production for the Aerospace Industry

STUDIO PILATES INTERNATIONAL ANNOUNCES 100TH STUDIO, WITH CONTINUED EXPANSION AND MILESTONE OPENING

NEW YORK, April 23, 2024 /PRNewswire/ -- Studio Pilates International , has just announced their continued expansion with their100th studio worldwide, and their 7th US opening in Chanhassen, Minnesota

2024-04-23 21:00 481

Zepp Health Corporation Files 2023 Annual Report on Form 20-F

MILPITAS, Calif., April 23, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today announced that it has filed its annual report on Form 20-F for the full year endedDecember 31, 2023 with the U.S. Securities and Exchange Commission (the "SEC"). The annual repor...

2024-04-23 20:20 515

OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market

SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-oncology drug candidates, to share technology and clinical ...

2024-04-23 18:37 1017

HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)

SAN DIEGO and WUHAN, China, April 23, 2024 /PRNewswire/ -- HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the N...

2024-04-23 14:54 712

Brise Pharmaceuticals Raises nearly $20M in Series Pre-A and Pre-A+ Financing

SHANGHAI, April 22, 2024 /PRNewswire/ -- Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately$20 million. This Pre-A round is led by Shunxi F...

2024-04-23 08:00 725

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024

* Preclinical data from the next generation eyedrop platform to be unveiled for the first time at ARVO 2024 DAEJEON, South Korea, April 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therap...

2024-04-23 07:25 960

Datasea Inc. (NASDAQ: DTSS) and iPower Inc. (NASDAQ: IPW) Collaborate to Expand Product Distribution in US Online Markets

BEIJING, April 22, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a trailblazing digital technology company incorporated in Nevada, dedicated to innovative solutions in acoustic high tech and 5G-Artificial Intelligence ("AI") multimodal communication technology inth...

2024-04-22 22:00 813

Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial

Trial results anticipated in early Q3 this year SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD)....

2024-04-22 20:30 663

Leo Cancer Care Teams up With World-Leading Carbon Ion Centre

Partnership will see Upright Radiotherapy System Installed at World-Leading Cancer Centre MIDDLETON, Wis., April 22, 2024 /PRNewswire/ -- Leo Cancer Care's unique upright radiotherapy solution is set to be installed in one of the world's most advanced oncology centres to deliver proton and carbo...

2024-04-22 18:43 912

Leo Cancer Care Teams up With World-Leading Carbon Ion Centre

Hyundai Bioscience announces its successful result from a preclinical study of a Niclosamide-based oral anticancer drug to treat triple-negative breast cancer

* Clinical trials of Niclosamide-based oral metabolic anticancer drug to commence for patients with difficult-to-treat cancers such as triple-negative breast cancer and pancreatic cancer * Niclosamide-based oral anticancer drug project to be carried out by the new subsidiary of Hyundai Biosci...

2024-04-22 17:51 818

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

SUZHOU, China, April 21, 2024 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced thatthe China phase II clinical trial (the "Phase II Clinical Trial") of i...

2024-04-22 09:53 1267

Juniper Biologics Named "Pharmaceutical Company of the Year" at Corporate LiveWire Global Awards

SINGAPORE, April 18, 2024 /PRNewswire/ -- Juniper Biologics

2024-04-22 09:00 915

Concord Medical Files 2023 Annual Report on Form 20-F

BEIJING, April 19, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it filed its annual report on Form 20-F for t...

2024-04-19 20:31 2216

MGI Tech's DNBSEQ-T20x2* Gene Sequencer Named 2024 Edison Award™ Gold Winner

FORT MYERS, Fla., April 19, 2024 /PRNewswire/ -- MGI Tech , a company committed to building core tools and technology to lead life science, is proud to announce that its DNBSEQ-T20x2* gene sequencer has been recognized with a GoldEdison Award

2024-04-19 20:15 944

GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer

SHANGHAI, April 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a mult...

2024-04-19 19:00 1729

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

SEOUL, South Korea, April 18, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi,www.hyundaibioscience.com ) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue...

2024-04-19 10:54 1826

TaiGen Successfully Completes TG-1000 Phase III Study

TAIPEI, April 17, 2024 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to alleviation of al...

2024-04-18 11:03 1156

Datasea Secures Combined $15 Million with its Second Sales Contract for Acoustic Products

BEIJING, April 17, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence ("AI") multimodal communication technology inthe United State...

2024-04-17 22:00 1045

Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity

SHANGHAI, April 17, 2024 /PRNewswire/ -- On April 17, 2024, Henlius (2696.HK) released its 2023 Environmental, Social and Governance (ESG) report (hereinafter referred to as "ESG report" or "report"). The report comprehensively discloses the Company's initiatives and achievements in promoting is...

2024-04-17 20:32 1282

12 3 4 5 ... 254